Altimmune Inc (MEX:ALT1)
MXN 183 0 (0%) Market Cap: 12.80 Bil Enterprise Value: 9.96 Bil PE Ratio: 0 PB Ratio: 4.66 GF Score: 37/100

Altimmune Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference Transcript

Oct 18, 2022 / 07:00PM GMT
Release Date Price: MXN194
Patrick Trucchio
HC Wainwright - Analyst

Welcome back, everyone, to the 3rd Annual HC Wainwright HVB conference. My name is Patrick Trucchio. I'm a senior biotech analyst at HC Wainwright. My pleasure to introduce our next presenter, Scot Roberts, CSO of Altimmune, a clinical-stage biopharmaceutical company focused on development of novel peptide-based therapeutics for treatment of obesity and liver diseases.

So maybe we can begin first with some discussion around Altimmune's synthetic peptide technology platform. How did it come to be in its current form? And what makes it differentiated from others on the market?

Scot Roberts
ALTIMMUNE, INC. - Chief Scientific Officer

Sure. Well, first of all, thank you for inviting me here, Patrick. It's a pleasure to talk about the HBV program, we call it HepTcell. So to your question, what's the technology and how is it different? So as it relates to HepTcell, and this is unique to that particular asset and not for our obesity or NASH program, the Pemvidutide.

But with respect to HepTcell, the goal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot